Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies
Authors:
- 1 October 2010
- journal article
- review article
- Published by Elsevier in Trends in Biotechnology
- Vol. 28 (10) , 509-516
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpuraEuropean Journal of Haematology, 2009
- Making autoantibodies safeProceedings of the National Academy of Sciences, 2008
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Neutralizing antibodies to biological therapiesNeurology, 2007
- Agalactosylated IgG antibodies depend on cellular Fc receptors forin vivoactivityProceedings of the National Academy of Sciences, 2007
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosisClinical Therapeutics, 2004
- Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with BiotinCancer Biotherapy and Radiopharmaceuticals, 2002
- Improved Tumor Localization and Radioimaging with Chemically Modified Monoclonal AntibodiesCancer Biotherapy and Radiopharmaceuticals, 1996
- Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationizationJournal of Pharmaceutical Sciences, 1995